TRIAL DATA
Phase II trial tests UGT1A1 genotype-guided high-dose irinotecan rechallenge in refractory metastatic CRCThis single-arm phase II study investigated whether patients with refractory metastatic colorectal cancer who previously responded to irinotecan could benefit from high-dose irinotecan rechallenge, with dosing adjusted based on UGT1A1 genotype to balance efficacy and safety. (Frontiers in Oncology)